Evidence map›Paper›PMID 36257974›Full record

ArticleScientific reports2022

Trough anti-Xa activity after intermediate dose nadroparin for thrombosis prophylaxis in critically ill patients with COVID-19 and acute kidney injury.

R J Eck, J J C M van de Leur, R Wiersema, E G M Cox, W Bult, A J Spanjersberg, I C C van der Horst, M V Lukens, R O B Gans, K Meijer and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 85% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

R J EckDepartment of Internal Medicine, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, 9700 RB, Groningen, The Netherlands. r.j.eck@umcg.nl.
J J C M van de LeurDepartment of Laboratory Medicine and Thrombosis Expertise Centre, Isala, Zwolle, The Netherlands.
R WiersemaDepartment of Critical Care, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
E G M CoxDepartment of Critical Care, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
W BultDepartment of Critical Care, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
A J SpanjersbergDepartment of Anesthesiology and Intensive Care, Isala, Zwolle, The Netherlands.
I C C van der HorstDepartment of Intensive Care, Maastricht University Medical Center+, Maastricht, The Netherlands.
M V LukensDepartment of Laboratory Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
R O B GansDepartment of Internal Medicine, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, 9700 RB, Groningen, The Netherlands.
K MeijerDepartment of Haematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
F KeusDepartment of Critical Care, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
University Medical Center Groningen · NLUniversity of Groningen · NLIsala · NLMaastricht University · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Our objective was to assess the incidence of drug bioaccumulation in critically ill COVID-19 patients with AKI receiving intermediate dose nadroparin for thrombosis prophylaxis. We conducted a Prospective cohort study of critically ill COVID-19 patients. In patients on intermediate dose nadroparin (5700 IU once daily) we assessed the incidence of bioaccumulation (trough anti-Xa level > 0.2 IU/mL) stratified according to presence of AKI. We quantified this association using multilevel analyses. To assess robustness of our observations, we explored the association between AKI and anti-Xa activity in patients receiving high dose nadroparin (> 5700 IU). 108 patients received intermediate dose nadroparin, of whom 24 had AKI during 36 anti-Xa measurements. One patient with AKI (4.2% [95%CI 0.1-21%]) and 1 without (1.2% [95%CI 0.03-6.5%]) developed bioaccumulation (p = 0.39). Development of AKI was associated with a mean increase of 0.04 (95%CI 0.02-0.05) IU/ml anti-Xa activity. There was no statistically significant association between anti-Xa activity and AKI in 51 patients on high dose nadroparin. There were four major bleeding events, all in patients on high dose nadroparin. In conclusion, Bioaccumulation of an intermediate dose nadroparin did not occur to a significant extent in critically ill patients with COVID-19 complicated by AKI. Dose adjustment in AKI may be unnecessary.

Indexed as

Acute Kidney InjuryCOVID-19ThrombosisAnticoagulantsCritical IllnessHumansNadroparinProspective StudiesAnticoagulantsNadroparin

Identifiers

PMID36257974
PMCPMC9579123
OpenAlexW4306734951

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.